Delving into the Latest Updates on Metronidazole with Synapse

Overview

Basic Info

SummaryMetronidazole, a small molecule drug approved in 1960 by Pfizer Inc., inhibits DNA synthesis and is highly effective against anaerobic bacteria and protozoa. Its versatility is demonstrated by its indication for a wide range of conditions, including skin ulcers, enteritis, Helicobacter pylori infection, rosacea, trichomonas vaginitis, and amebiasis. By disrupting DNA synthesis, metronidazole inhibits growth and multiplication of these microorganisms. It also shows potential as a substitute therapy for some antibiotic-resistant bacterial infections. However, like all drugs, metronidazole has potential adverse effects such as nausea, regurgitation, and metallic taste in the mouth. Patients should carefully follow prescribed dosages and treatment durations to avoid antibiotic resistance and the risk of side effects.

Drug Type

Small molecule drug

Synonyms

1-(2-hydroxy-1-ethyl)-2-methyl-5-nitroimidazole, 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole, 1-(β-ethylol)-2-methyl-5-nitro-3-azapyrrole

+ [94]

Target-

Action

inhibitors

Mechanism

DNA synthesis inhibitors

Therapeutic Areas

Infectious DiseasesNervous System DiseasesCardiovascular Diseases+ [6]

Active Indication

GiardiasisGingivitis, Necrotizing UlcerativeTooth Infection+ [23]

Inactive Indication

Complicated intra-abdominal infectionCrohn DiseaseHemorrhoids+ [5]

Originator Organization

Pfizer Inc.

Active Organization

Hospira, Inc.

Pfizer Inc.Galderma Laboratories LP

+ [12]

Inactive Organization

S.L.A. Pharma AG

Braintree Laboratories, Inc.

Appili Therapeutics, Inc.

License Organization

Appili Therapeutics, Inc.

Sanofi

Fidia Farmaceutici SpA

+ [2]

Drug Highest PhaseApproved

First Approval Date

France (01 Jan 1960),

Bacterial VaginosisEndocarditisPelvic Inflammatory Disease

RegulationOrphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC6H9N3O3

InChIKeyVAOCPAMSLUNLGC-UHFFFAOYSA-N

CAS Registry443-48-1

Management of non-vital primary molars is challenging due to the natural anatomy of primary teeth, patients' young age, and their behavior toward dental treatment. A simple and effective technique such as Lesion Sterilization and Tissue Repair offers a solution to cases with poor prognosis; however, the medicaments used in this technique have some limitations. This study will evaluate three different medicaments regarding the clinical success, radiographic success, and antibacterial activity.

Start Date01 Aug 2025

Sponsor / Collaborator

Ain Shams University

ChiCTR2500104165

Not ApplicableIIT

Randomized Controlled Trial of Vonoprazan-Metronidazole-Bismuth Quadruple Therapy with Varying Durations for Helicobacter pylori Eradication: A Single-Center Study

Start Date01 Jul 2025

Sponsor / Collaborator-

100 Clinical Results associated with Metronidazole

Login to view more data

100 Translational Medicine associated with Metronidazole

Login to view more data

100 Patents (Medical) associated with Metronidazole

Login to view more data

26,409

Literatures (Medical) associated with Metronidazole

31 Dec 2025·Emerging Microbes & Infections

Genomic islands and molecular mechanisms relating to drug-resistance in Clostridioides ( Clostridium ) difficile PCR ribotype 176

Article

Author: Soltesova, Anna ; Pituch, Hanna ; Kuijper, Ed ; Balikova Novotna, Gabriela ; Brajerova, Marie ; Prasad, Suhanya ; Zikova, Jaroslava ; Demay, Fanny ; Novakova, Elena ; Kovarovic, Vojtech ; Krutova, Marcela ; Smits, Wiep Klaas

OBJECTIVES:

To analyse characteristics of Clostridioides difficile PCR ribotype 176 clinical isolates from Poland, the Czech Republic and Slovakia with regard to the differences in its epidemiology.

METHODS:

Antimicrobial susceptibility testing and whole genome sequencing were performed on a selected group of 22 clonally related isolates as determined by multilocus variable-number tandem repeat analysis (n = 509). Heterologous expression and functional analysis of the newly identified methyltransferase were performed.

RESULTS:

Core genome multilocus sequence typing found 10-37 allele differences. All isolates were resistant to fluoroquinolones (gyrA_p. T82I), aminoglycosides with aac(6')-Ie-aph(2'')-Ia in six isolates. Erythromycin resistance was detected in 21/22 isolates and 15 were also resistant to clindamycin with ermB gene. Fourteen isolates were resistant to rifampicin with rpoB_p. R505K or p. R505K/H502N, and five to imipenem with pbp1_p. P491L and pbp3_p. N537K. PnimB^G together with nimB_p. L155I were detected in all isolates but only five were resistant to metronidazole on chocolate agar. The cfrE, vanZ1 and cat-like genes were not associated with linezolid, teicoplanin and chloramphenicol resistance, respectively. The genome comparison identified six transposons carrying antimicrobial resistance genes. The ermB gene was carried by new Tn7808, Tn6189 and Tn6218-like. The aac(6')-Ie-aph(2'')-Ia were carried by Tn6218-like and new Tn7806 together with cfrE gene. New Tn7807 carried a cat-like gene. Tn6110 and new Tn7806 contained an RlmN-type 23S rRNA methyltransferase, designated MrmA, associated with high-level macrolide resistance in isolates without ermB gene.

CONCLUSIONS:

Multidrug-resistant C. difficile PCR ribotype 176 isolates carry already described and unique transposons. A novel mechanism for erythromycin resistance in C. difficile was identified.

31 Dec 2025·JOURNAL OF DERMATOLOGICAL TREATMENT

Rosacea-like skin reaction under treatment with dupilumab for atopic dermatitis

Article

Author: Augustin, M. ; Wagner, J. N. ; Zirkenbach, F. ; Grote, C.

PURPOSE:

Dupilumab is a widely recommended treatment for moderate-to-severe atopic dermatitis (AD), with known ocular side effects but less frequent cutaneous reactions.

MATERIAL AND METHODS:

This case report details a 52-year-old female patient with atopic dermatitis treated with dupilumab. After an initially successful treatment, the patient developed a rosacea-like dermatitis. At first, dupilumab was continued alongside doxycycline, metronidazole gel and ivermectin cream.

RESULTS:

Following a worsening of her skin condition, dupilumab was discontinued. Lebrikizumab was introduced, leading to significant regression of the lesions.

CONCLUSIONS:

This case highlights a rare paradoxical skin reaction to dupilumab, potentially linked to the blockade of IL-4Rα, which may shift the immune response towards a Th1/Th17 phenotype. The findings suggest that alternative therapies, such as IL-13 inhibitors, should be considered when cutaneous side effects arise during dupilumab treatment.

31 Dec 2025·Journal of Oral Microbiology

Amoxicillin-metronidazole disk for antimicrobial susceptibility testing of subgingival bacteria

Article

Author: Frandsen Lau, Ellen ; Jensen, Anne Birkeholm ; Nørskov-Lauritsen, Niels

Background:

Antibiotics are used in periodontal therapy in selected cases, but therapy is rarely guided by antimicrobial susceptibility testing (AST). Direct AST of the oral microbiota using a combination disk with different antibiotics could provide a new way of AST to guide treatment planning.

Methods:

We performed AST of 46 strains of Aggregatibacter actinomycetemcomitans, Fusobacterium nucleatum complex, Prevotella species, and Porphyromonas gingivalis, with a combination disk of amoxicillin (AMX) and metronidazole (MET). The AMX-MET was compared to the largest inhibition zone diameter (IZD) obtained with AMX or MET disks, using an ordinary least square linear regression model.

Results:

The IZD of the AMX-MET correlated with the AMX for A. actinomycetemcomitans (interception 0.3) and with the MET for Fusobacterium (interceptions -1.25). For Prevotella, the AMX-MET was compared to AMX and MET after 20 and 44 h resulting in a superior correlation after 20 h (interception 0.06 vs 6.61 after 44 h). For P. gingivalis, the AMX-MET was compared to MET after 44 h resulting in an inferior correlation (interception 16.65).

Conclusion:

The IZD of AMX-MET was comparable to that of AMX and MET for important periodontal pathogens, which opens for studies on direct AST of oral samples with a mixed microbiota.

Key message:

The amoxicillin-metronidazole disk for antimicrobial susceptibility testing results in comparable inhibition zone diameters to that of AMX and MET for important periodontal pathogens.

75

News (Medical) associated with Metronidazole

19 Aug 2025

·www.prnewswire.com

FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis

-- Evofem now holds eleven Orange Book - listed patents covering SOLOSEC into late 2041 -- SAN DIEGO, Aug. 19, 2025 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCID: EVFM) today announced that a newly-issued U.S. patent which covers SOLOSEC® (secnidazole) 2 g oral granules and one of its labeled indications is now listed in the U.S. Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. "The Orange Book listing of this patent covering SOLOSEC's method, pharmaceutical composition, and use in trichomoniasis is an important step in further strengthening our patent portfolio," said Evofem Biosciences CEO Saundra Pelletier. "The patent itself extends SOLOSEC's intellectual property and market exclusivity into December 2041, which significantly benefits prescribers, patients, and our investors with a longer opportunity to build the SOLOSEC brand – the first and only single-dose oral treatment FDA-approved to treat BV as well as trichomoniasis – in the U.S." The newly listed U.S. Patent No. 12,280,037 (the '037 patent) covers "method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof". The '037 patent was issued by the U.S. Patent and Trademark Office (USPTO) on April 22, 2025 and is expected to expire in December 2041. It is directed to treatment of Trichomonas vaginalis infections (trichomoniasis) with SOLOSEC, with broad claims centered on pharmacokinetics and formulation features of Evofem's single-dose oral antimicrobial agent. Trichomoniasis is the most common non-viral sexually transmitted infection in the world. There are an estimated 6.9 million new infections with T. vaginalis in the U.S. each year.1 Undiagnosed infections and lack of compliance with multi-day treatment regimens are critical contributing factors. All sexual partners of people infected with trichomoniasis should be treated with the same dose and at the same time to prevent reinfection. SOLOSEC® is designed to be easy to take; one oral dose contains a complete course of treatment. Patient recruitment is underway in an investigator-led, NIH-funded Phase 4 clinical trial evaluating the effectiveness and cost-effectiveness of SOLOSEC (single-dose, one time) versus metronidazole (twice daily for seven days) for the treatment of T. vaginalis in men and women. Study investigators hypothesize that the rate of repeat infections with T. vaginalis will be 1.75 lower in the SOLOSEC arm versus the multi-dose oral metronidazole arm and that single-dose SOLOSEC will have higher initial cost but will be more cost effective compared to multi-dose metronidazole, largely due to lower breakthrough rates of infection. 2 About Evofem Biosciences Evofem is commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company generates revenue from the sale of two FDA-approved products. PHEXXI® (lactic acid, citric acid, and potassium bitartrate), is the first and only hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Visit phexxi.com to learn more and for important safety information. SOLOSEC® (secnidazole) 2g oral granules is an FDA-approved oral antibiotic for the treatment of two sexual health diseases: bacterial vaginosis (BV), a common vaginal infection, in females 12 years of age and older, and trichomoniasis, a common sexually transmitted infection (STI), in people 12 years of age and older. SOLOSEC provides a complete course of therapy in just one dose. Visit solosec.com to learn more and for important safety information. Evofem filed a preliminary proxy on July 24, 2025 regarding its planned Special Meeting of Stockholders at which stockholders of record may vote on a proposal to approve the transactions contemplated under the A&R Merger Agreement between the Company, Aditxt, Inc. (NASDAQ: ADTX) and Adifem, Inc., a wholly owned subsidiary of Aditxt. Under the A&R Merger Agreement, Adifem will merge with and into the Company, with Evofem surviving as a wholly owned subsidiary of Aditxt. A definitive proxy filing is expected in a few weeks. PHEXXI® and SOLOSEC® are registered trademarks of Evofem Biosciences, Inc. Sources Kreisel KM et al. Sexually Transmitted Infections Among US Women and Men: Prevalence and Incidence Estimates, 2018. Sex Transm Dis. 2021 Apr 1;48(4):208-214. doi: 10.1097/OLQ.0000000000001355. PMID: 33492089; PMCID: PMC10245608. National Institute of Allergy & Infectious Diseases (NIAID) of the National Institutes of Health. Award number R01AI183266: Refining Trichomonas vaginalis treatment in women and men. Forward-Looking Statements This press release includes "forward-looking statements," within the meaning of the safe harbor for forward-looking statements provided by Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "anticipate," "aim," "believe," "contemplate," "continue," "could," "design," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "seek," "should," "suggest," "strategy," "target," "will," "would," and similar expressions or phrases, or the negative of those expressions or phrases, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include but are not limited to anticipated timing of the definitive proxy filing regarding the planned Special Meeting of Stockholders. The closing of the transactions with Evofem, Aditxt and Adifem, Inc., contemplated by the A&R Merger Agreement are subject to several conditions including, but not limited to, 1) approval of the transactions by a majority of the combined voting power of Evofem's E-1 and Common Stock, voting together as a single class, at a meeting where quorum is present, and 2) Aditxt raising sufficient capital to fund its closing obligations, notably a cash payment of approximately $15 million required to satisfy Evofem's senior secured noteholder. Should Aditxt fail to secure these funds, Evofem's senior secured noteholder is expected to seek to prevent the closing of the merger. No assurance can be provided that all of the conditions to closing will be obtained or satisfied or that the transaction will ultimately close. You are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Important factors that could cause actual results to differ materially from those discussed or implied in the forward-looking statements are disclosed in the Company's SEC filings, including its Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 24, 2025, amended on March 28, 2025, Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, filed with the SEC on August 14, 2025, and any subsequent filings. All forward-looking statements are expressly qualified in their entirety by such factors. The Company does not undertake any duty to update any forward-looking statement except as required by law. No Offer or Solicitation This release shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed transactions under the A&R Merger Agreement. This release shall also not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such other jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom. Connect with Us Join the Dialogue Media [email protected] Investors and Potential Partners Amy Raskopf, Chief Business Development Officer Evofem Biosciences, Inc. [email protected] (917) 673-5775 SOURCE Evofem Biosciences, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3Drug ApprovalAcquisition

30 May 2025

·www.globenewswire.com

Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 30, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced that, in response to the notice received from Aditxt Inc. (“Aditxt”) on May 17, 2025, the Company has delivered formal notice to Aditxt to terminate the arrangement agreement (the “Arrangement Agreement”) dated April 1, 2024 (as amended) between the Company, Aditxt and its wholly-owned subsidiary, Adivir, Inc. (“Adivir”). Such termination is effective as of May 30, 2025. Under the Arrangement Agreement, the Company is entitled to a termination fee (the “Termination Fee”) in the amount of USD$1,250,000 payable by Aditxt. This Termination Fee has been reduced by certain amounts previously paid to the Company by Aditxt to extend the outside date under the Arrangement Agreement. As of the date hereof, the amount of US$1,000,000 remains payable to Appili on account of the Termination Fee. Lender Extensions In connection with the termination of the Arrangement Agreement, Appili has secured 3-month extensions to the amounts due under each of (1) the amended and restated secured loan agreement with Long Zone Holdings Inc. (the “LZH Loan”), and (2) the unsecured promissory notes with Bloom Burton & Co. Inc. (the “Bloom Burton Loan”). Pursuant to the terms of such extensions, all amounts owing under the LZH Loan and the Bloom Burton Loan, together with all accrued and unpaid interest, will be due on August 31, 2025. About Appili Therapeutics Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. For more information, visit www.AppiliTherapeutics.com. Forward Looking Statements This news release contains “forward-looking information” within the meaning of applicable securities laws. Forward-looking information contained in this press release may be identified by the use of words such as, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” and other similar expressions. Forward-looking information is not a guarantee of future performance and is based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors relevant in the circumstances, including assumptions in respect of current and future market conditions, the current and future regulatory environment, and the availability of licenses, approvals and permits. Forward-looking statements in this news release include, but are not limited to statements with respect to the payment of the Termination Fee and the repayment deadline under the LZH Loan and the Bloom Burton Loan. Actual results and developments may differ materially from those contemplated by these statements. Such forward-looking statements are based on certain assumptions regarding Aditxt and Appili. While Appili considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Forward-looking information is subject to a variety of risks and uncertainties that could cause actual events or results to differ materially from those projected in the forward-looking information. Such risks and uncertainties include, but are not limited to, risks relating to the termination of the proposed transaction, the ability of Appili to collect the Termination Fee (and the timing thereof), the impact of the potential termination of the proposed transaction on Appili and its operations and such other risks as were identified in the management information circular of the Company dated as of October 4, 2024, a copy of which is available on SEDAR+ at www.sedarplus.ca/. The statements in this press release are made as of the date of this release. Appili disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. No securities regulatory authority has either approved or disapproved of the contents of this press release. This press release is for information purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Neither CIRO nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release. Media Contact: Jenna McNeil, Corporate Affairs and Communications Manager Appili Therapeutics E: JMcNeil@AppiliTherapeutics.com Investor Relations Contact: Don Cilla, Pharm.D. M.B.A. Appili Therapeutics E: Info@AppiliTherapeutics.com

Vaccine

21 May 2025

·www.globenewswire.com

Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.

May 19, 2025 -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, announced that Aditxt, Inc. (“NASDAQ:ADTX”) (“Aditxt”) has delivered notice (the “Termination Notice”) purporting to terminate the arrangement agreement dated April 1, 2024 between the Company, Aditxt, and its wholly-owned subsidiary, Adivir, Inc. (“Adivir”) (as amended on July 1, 2024 and further amended on July 17, 2024 and as further amended on August 20, 2024, the “Arrangement Agreement”), such termination to be effective as of May 31, 2025. Under the Arrangement Agreement, the Company is entitled to a termination fee (the “Termination Fee”) in the amount of USD$1,250,000 payable by Aditxt upon termination of the Arrangement Agreement in certain circumstances. This Termination Fee is to be reduced by certain amounts previously paid to the Company by Aditxt to extend the outside date under the Arrangement Agreement. As of the date hereof, the amount of US$1,000,000 would be payable to Appili on account of the Termination Fee. Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives. The Company is currently advancing a diverse range of anti-infectives, including an FDA approved ready-made suspension of metronidazole for the treatment of antimicrobial infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Led by a proven management team, Appili is at the epicenter of the global fight against infection. Such forward-looking statements are based on certain assumptions regarding Aditxt and Appili, including the validity of the Termination Notice, remedies available to Appili as a result of the Termination Notice and that Aditxt will not revoke the Termination Notice. While Appili considers these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. The content above comes from the network. if any infringement, please contact us to modify.

VaccineLicense out/inQualified Infectious Disease Product

100 Deals associated with Metronidazole

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00409	Metronidazole	G01AF01 D06BX01 J01XD01	DB00916

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Giardiasis	South Korea	Chodang Pharm Co., Ltd.	06 Sep 2024
Gingivitis, Necrotizing Ulcerative	South Korea	Chodang Pharm Co., Ltd.	06 Sep 2024
Tooth Infection	South Korea	Chodang Pharm Co., Ltd.	06 Sep 2024
Liver Abscess, Amebic	United States	Saptalis Pharmaceuticals LLC	22 Sep 2023
Skin Ulcer	Japan	Maruho Co., Ltd.	26 Dec 2014
Helicobacter-associated gastritis	Japan	Shionogi Pharma Co., Ltd.	21 Feb 2013
Infectious enteritis	Japan	Shionogi Pharma Co., Ltd.	10 Aug 2012
Neuroschistosomiasis	Japan	Shionogi Pharma Co., Ltd.	10 Aug 2012
Helicobacter pylori infection	Japan	Shionogi Pharma Co., Ltd.	23 Aug 2007
Rosacea	United States	Bausch Health US LLC	26 Sep 1997
Trichomonas Vaginitis	United States	Pfizer Inc.	03 May 1995
Infectious Diseases	China	Tianjin Lisheng Pharmaceutical Co., Ltd.	01 Jan 1981
Amebiasis	United States	Pfizer Inc.	18 Jul 1963
Anaerobic bacterial infection	United States	Pfizer Inc.	18 Jul 1963
Bone and joint infections	United States	Pfizer Inc.	18 Jul 1963
Central Nervous System Infections	United States	Pfizer Inc.	18 Jul 1963
Gynecological infection	United States	Pfizer Inc.	18 Jul 1963
Intraabdominal Infections	United States	Pfizer Inc.	18 Jul 1963
Lower Respiratory Tract Infections	United States	Pfizer Inc.	18 Jul 1963
Sepsis	United States	Pfizer Inc.	18 Jul 1963

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Gram-Negative Bacterial Infections	Phase 3	United States	Pfizer Inc.	05 Apr 2018
Gram-Negative Bacterial Infections	Phase 3	China	Pfizer Inc.	05 Apr 2018
Gram-Negative Bacterial Infections	Phase 3	Argentina	Pfizer Inc.	05 Apr 2018
Gram-Negative Bacterial Infections	Phase 3	Bulgaria	Pfizer Inc.	05 Apr 2018
Gram-Negative Bacterial Infections	Phase 3	Croatia	Pfizer Inc.	05 Apr 2018
Gram-Negative Bacterial Infections	Phase 3	Czechia	Pfizer Inc.	05 Apr 2018
Gram-Negative Bacterial Infections	Phase 3	Greece	Pfizer Inc.	05 Apr 2018
Gram-Negative Bacterial Infections	Phase 3	India	Pfizer Inc.	05 Apr 2018
Gram-Negative Bacterial Infections	Phase 3	Israel	Pfizer Inc.	05 Apr 2018
Gram-Negative Bacterial Infections	Phase 3	Italy	Pfizer Inc.	05 Apr 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02042287 (Pubmed \| BMC Womens Health)	Phase 4	Bacterial Vaginosis	32	Lactic acid vaginal gel	lqednuehpa(snwioxmkpx) = after up to six months ljtdzuhzzj (iawbwnwhsp ) View more	Positive	06 Jan 2025
NCT02185209 (Pubmed \| J Clin Periodontol)	Phase 4	Peri-Implantitis	-	Amoxicillin and Metronidazole	iungxlzxsl(euuuhsbuil) = fftfetwhgz ifxjkmonks (xybaaetuwu ) View more	Positive	01 Aug 2024
				Phenoxymethylpenicillin and Metronidazole	iungxlzxsl(euuuhsbuil) = zfyommzgyh ifxjkmonks (xybaaetuwu ) View more
NCT03329092 (REVISIT, CTgov)	Phase 3	Complicated intra-abdominal infection \| Gram-Negative Bacterial Infections \| Pneumonia, Ventilator-Associated ... View more	422	MTZ+ATM-AVI	gnopcrsgeg = qbmsvmwyra zqfdbhscqv (hgnmlsggxr, quwifzkqqi - emvkspqmez) View more	-	07 May 2024
NCT04478617 (PROJECT PREVENT, Pubmed)	Phase 4	Infectious Diseases	133	Vaginal metronidazole for 5 days before hysterectomy	vmoyetkrlw(hidkibodoz) = ubthxuyqle gftcvxddzn (wtadyrieky ) View more	Negative	01 Apr 2024
				vaginal metronidazole (No intervention)	vmoyetkrlw(hidkibodoz) = xaftdejbjo gftcvxddzn (wtadyrieky ) View more
NCT04927312 (CTgov)	Phase 3	Complicated intra-abdominal infection	60	PF-06947386+Metronidazole	xzdkjojtaa = okkhstnvyo xayydotihi (wqxognsxqh, vzuzhtcdws - yzrmjtxrvy) View more	-	08 Mar 2024
NCT03917134 (Pubmed \| J Minim Invasive Gynecol)	Not Applicable	Parametritis bacterial vaginosis	574	Cefazolin 2g + Metronidazole vaginal ovules	tzgzwkutni(qyrczxuddy) = miywqnbyma jejgtimync (fqxbzjvmlu )	Negative	01 Nov 2023
				Cefazolin 2g + Placebo vaginal ovules	tzgzwkutni(qyrczxuddy) = buovuuxcjr jejgtimync (fqxbzjvmlu )
ISRCTN14161293 (VITA, Pubmed \| Int J STD AIDS)	Phase 3	-	155	Oral Metronidazole 400mg	tepkrjimtq(salatfazda) = 99/155 reported at least one metronidazole AE, including 72/155 who reported gastrointestinal symptoms mostly within 3 days of starting treatment and resolving within 5 days of onset. Treatment discontinuation occurred in 8% (12/148) overall and AEs were given as the reason for discontinuing in only 3% (4/148) xxqyihplui (naxqfsihjd )	Positive	01 Oct 2023
SGO2023	Not Applicable	Female Genital Neoplasms	-	First or second-generation cephalosporins	aydccyrdht(hdsxyjblhq) = logrlixwio uwxbzdkffa (yuikzlpcga )	-	01 Sep 2023
				Metronidazole	aydccyrdht(hdsxyjblhq) = krvggrshcs uwxbzdkffa (yuikzlpcga )
NCT04578015 (CTgov)	Phase 4	Bacterial Vaginosis	16	Metronidazole (Metronidazole 500 mg)	rpsrqudlgb(otsehxsxkp) = ctiekutpct vxgmsnujgt (udmdslfqqb, nfciyzngaj - rupjjomfto) View more	-	15 Jun 2023
				Placebo (Placebo)	rpsrqudlgb(otsehxsxkp) = eiwrzuebgw vxgmsnujgt (udmdslfqqb, ebrqxsfztg - dqraffzvrj) View more
NCT03557008 (CTgov)	Phase 4	Rabies	37	Rabies Vaccine+Metronidazole+Neomycin Sulfate+Vancomycin (Rabies Vaccine With Antibiotics)	mxigtxsqtr(rhzpctvmcn) = pfqtlumjwo nuhapvricu (sqprbxdvjc, 262.99) View more	-	08 Jun 2023
				Rabies Vaccine (Rabies Vaccine)	mxigtxsqtr(rhzpctvmcn) = szgqlhcywn nuhapvricu (sqprbxdvjc, 943.85) View more